Summarized by Masters of Longevity from BioSpace - Funding.
Remedy secured $62 million to fund trials and regulatory progress for N1.

Key Takeaways
- Remedy raised $62 million in a Series B funding round.
- Funding is supporting a planned pivotal trial with University of California.
- Advancement toward FDA approval and prototype deployments were planned.



